Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: vildagliptin + metformin Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 418 participants
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: Vildagliptin, metformin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin + metformin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 530 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin, glimepiride, Metformin, Vildagliptin matching placebo, Glimepiride matching placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 73 Years
Enrollment: 3,118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin + metformin, metformin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 16
States / cities: Pine Bluff, Arkansas • Long Beach, California • Denver, Colorado + 11 more

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 588 participants
Timeline: Started 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin, thiazolidinedione (TZD); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,665 participants
Timeline: Started 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: Vildagliptin AM, vildagliptin pm, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: Vildagliptin, Metformin, Vildagliptin + Metformin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 1,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)

Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes

Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes